Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Share-based Compensation (2021 - 2025)

Oncology Institute (TOI) has disclosed Share-based Compensation for 5 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 57.14% year-over-year to $1.0 million, compared with a TTM value of $4.5 million through Sep 2025, down 67.56%, and an annual FY2024 reading of $11.2 million, down 37.38% over the prior year.
  • Share-based Compensation was $1.0 million for Q3 2025 at Oncology Institute, up from $752000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $24.4 million in Q4 2021 and bottomed at $42000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $4.4 million, with a median of $4.1 million recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 20264.29% in 2022, then plummeted 77.8% in 2025.
  • Year by year, Share-based Compensation stood at $24.4 million in 2021, then crashed by 75.11% to $6.1 million in 2022, then plummeted by 32.8% to $4.1 million in 2023, then plummeted by 68.4% to $1.3 million in 2024, then dropped by 20.56% to $1.0 million in 2025.
  • Business Quant data shows Share-based Compensation for TOI at $1.0 million in Q3 2025, $752000.0 in Q2 2025, and $1.5 million in Q1 2025.